Research programme: metalloprotein inhibitors - Forge Therapeutics
Alternative Names: Metalloenzyme inhibitors - Forge TherapeuticsLatest Information Update: 28 Sep 2023
At a glance
- Originator Forge Therapeutics
- Class Anti-inflammatories; Antineoplastics; Small molecules
- Mechanism of Action Metalloprotein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; CNS disorders; Inflammation; Metabolic disorders
Most Recent Events
- 28 Sep 2023 No recent reports of development identified for research development in CNS-disorders in USA
- 28 Sep 2023 No recent reports of development identified for research development in Inflammation in USA
- 28 Sep 2023 No recent reports of development identified for research development in Metabolic-disorders in USA